Nepsis: Who we are
Nepsis Institute takes groundbreaking stem cell technology and methodology created by US scientists and licenses it to select labs that provide stem cell processing services to appropriately credentialed and licensed physicians and researchers. In some instances Nepsis partners with clinics.
Nepsis owned and laboratories currently process autologous adipose (fat) derived stem cells, as well as disease-screened human umbilical cord and placental stem cells. In addition, following successful completion of safety studies, experimental clinical research involving the use of induced pluripotent stem cells (iPS) created from patient-participant's own liver cells without the use of viruses or harsh chemicals that can alter stem cell DNA will be conducted (The initial use will be restricted to terminally ill patients). This innovative laboratory methodology was created in the US and is licensed to Nepsis Institute.
Nepsis also helps gather patient response data for analysis and eventual publication in the form of professional papers submitted to mainstream peer reviewed journals.
